Understanding this molecular basis is crucial for rational development of pharmacological inhibitors that specifically target NCX1 in the reverse mode, holding promising therapeutic potential in preventing Ca2+ overload and electrical dysfunction in the context of ischemia/reperfusion injury and heart failure (Chen and Li, 2012a; Imahashi et al, 2005). This evidence concerns the gene SLC8A1 and heart failure.